Comparative Pharmacology
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus TANZEUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXENATIDE SYNTHETIC versus TANZEUM.
EXENATIDE SYNTHETIC vs TANZEUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exenatide synthetic is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion, slowing gastric emptying, and promoting satiety.
Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneously 5 mcg twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month.
Subcutaneous injection: 300 mg every 4 weeks. Administer as 3 consecutive injections of 100 mg each in the same body region (abdomen, thigh, or upper arm).
None Documented
None Documented
Terminal elimination half-life is 2.4 hours for subcutaneous administration, supporting twice-daily dosing.
Terminal elimination half-life approximately 5 days (range 4-6 days), supporting weekly subcutaneous dosing
Primarily renal via glomerular filtration and proteolytic degradation; approximately 30% of the dose is excreted unchanged in urine, with the remainder as metabolites in urine and feces.
Renal (79% as unchanged drug), biliary/fecal (minor, ~1%)
Category A/B
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist